ZHBIO(SZ:300653)2022-02-28 16:00Revenue and Financial Performance - The company's operating revenue for 2021 was CNY 400,175,251.94, representing a 36.45% increase compared to CNY 293,281,582.66 in 2020[21]. - The net profit attributable to shareholders for 2021 was CNY 168,552,584.39, a 42.44% increase from CNY 118,333,984.88 in 2020[21]. - The net profit after deducting non-recurring gains and losses was CNY 160,878,004.21, up 46.35% from CNY 109,923,656.88 in 2020[21]. - The net cash flow from operating activities for 2021 was CNY 166,134,014.20, an increase of 40.28% compared to CNY 118,432,079.92 in 2020[21]. - The total assets at the end of 2021 were CNY 928,920,991.12, a 15.32% increase from CNY 805,539,145.17 at the end of 2020[21]. - The net assets attributable to shareholders at the end of 2021 were CNY 785,270,986.59, reflecting a 21.42% increase from CNY 646,718,402.20 at the end of 2020[21]. - The basic earnings per share for 2021 were CNY 1.40, a 41.41% increase from CNY 0.99 in 2020[21]. - The weighted average return on equity for 2021 was 23.62%, up from 19.16% in 2020, an increase of 4.46%[21]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the year, representing a growth of 15% year-over-year[117]. - The company reported a total revenue of 1.5 billion RMB in 2021, representing a growth of 20% compared to 2020[128]. Product Development and Market Expansion - The main revenue sources for the company are the oral repair membrane and absorbable dura (spinal) membrane patches, both of which are classified as Class III implantable medical devices, showing rapid growth in recent years[6]. - The company aims to develop innovative products in the field of regenerative medicine, focusing on repairing and reconstructing human tissues[32]. - The company is focused on improving its brand influence and clinical application of its products, which have received positive feedback in the market[6]. - The company is actively pursuing market expansion strategies, targeting new regions in Southeast Asia for its product distribution[121]. - New product development includes the launch of a bioactive bone material, which is expected to capture a larger market share in the dental implant sector[122]. - The company plans to expand its product offerings in the oral and soft tissue repair fields, enhancing its competitive advantage[78]. - The company has successfully participated in volume-based procurement in five provinces, including Jiangsu and Shandong, without significant pressure on performance, although future expansions of procurement may impact growth[6]. - The company received a registration certificate for a new product, "surgical packing sponge," which is expected to contribute to revenue growth[40]. - The company is in the process of registering several new products, including Active Biological Bone and Dura Mater Patch, with the latter currently in the registration submission phase[80]. Research and Development - The development and registration of new products involve complex processes with high R&D costs and long cycles, which carry inherent uncertainties[8]. - The company's R&D investment in 2021 amounted to ¥35,179,509.47, representing 8.79% of its operating revenue, a slight decrease from 9.06% in 2020[78]. - The number of R&D personnel increased by 18.52% from 54 in 2020 to 64 in 2021, with 72.22% of them being under 30 years old[78]. - The company is actively pursuing innovation with a focus on product development, including ongoing projects for dental and orthopedic applications[48][55]. - The company has established a comprehensive intellectual property protection system, including patent applications and confidentiality agreements with core technical personnel[114]. - The company holds 61 authorized patents and 88 registered trademarks as of December 31, 2021, indicating a strong intellectual property position[62]. Governance and Compliance - The company’s financial report has been verified by the board and management, ensuring its accuracy and completeness[4]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with governance standards[121]. - The company has established a governance structure that ensures independence from its controlling shareholders, maintaining a complete and autonomous business operation[125]. - The company has implemented measures to prevent fund occupation by controlling shareholders and related parties, protecting the interests of shareholders[166]. - The company has maintained a strong commitment to social responsibility, focusing on value creation and community support since its establishment[176]. - The company has established effective communication channels with investors, including a dedicated investor hotline and email, to maintain transparency[179]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[174]. - The company has established a robust internal control system in compliance with relevant laws and regulations, ensuring effective governance and management[165]. Employee and Compensation Management - The company employed 378 staff members by the end of the reporting period, reflecting a 15% increase compared to the end of 2020[57]. - The company has a total of 10 directors and senior management members listed, with varying remuneration amounts[139]. - The company has established a comprehensive salary management system, considering market demand and individual performance[152]. - The company has a structured approach to managing investor relations, with a designated secretary responsible for communication with investors[124]. - The company emphasizes employee training across various business themes, including strategic decision-making and quality management[153]. Risk Management - The company acknowledges risks related to concentrated product offerings and external environmental changes that may affect future performance[8]. - The company faces risks related to the lengthy and complex process of new product development and registration, which involves multiple stages and significant investment[109]. - The company is subject to industry policy changes and external environmental risks, particularly regarding high-value medical consumables and the ongoing healthcare reform[111]. - The quality of implanted medical devices is critical, as any quality issues could adversely affect patient health and the company's operations[112]. - The company has established a strict supplier evaluation system to mitigate risks associated with the quality of animal tissues used in its products, although national animal epidemics could pose challenges[112]. Cash Dividend and Profit Distribution - The company plans to distribute a cash dividend of 8.80 RMB per 10 shares (including tax) to all shareholders, based on a total of 120,000,000 shares, with no bonus shares issued[8]. - The company has a stable profit distribution policy, aiming for a cash dividend of at least 20% of the distributable profit if there are no major investment plans[155]. - The company has established a differentiated cash dividend policy, with a minimum of 80% cash dividend for mature stages without major expenditures[156]. - The company distributed a cash dividend of RMB 30,000,000.00 (including tax) to shareholders, amounting to RMB 2.5 per 10 shares based on 120,000,000 shares[177]. - For the reporting period, the company distributed a cash dividend of RMB 8.80 per 10 shares, amounting to a total of RMB 105.6 million, which represents 28.09% of the distributable profit of RMB 375,969,499.75[163].